AIM ImmunoTech is trading at $0.25 (+8.35%) after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment through June 2041.
- The announcement expands the company’s global intellectual-property estate across major European markets and strengthens potential commercial protection around Ampligen.
- The move follows a 0.59% decline on September 2; biotech-sector strength provides additional supportive background.